MacroGenics (MGNX) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MacroGenics (MGNX) has outperformed SIGA Technologies (SIGA) over the past year, gaining 99.4% versus a loss of 60.4%. Over five years, SIGA leads with a -53.9% price change compared with -82.0% for MGNX. SIGA Technologies is the larger company by market cap ($235.7 million vs $226.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | SIGA |
|---|---|---|
| Share price | $3.55 | $3.28 |
| Market cap | $226.14M | $235.67M |
| 1-day change | 0.00% | +0.61% |
| YTD return | +120.50% | -46.32% |
| 1-year return | +99.44% | -60.39% |
| 5-year return | -82.02% | -53.87% |
| Forward P/E | — | 3.04 |
| EPS (TTM) | $-1.70 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $8.55 |
| 52-week low | $1.29 | $2.83 |
| Distance from 52-week high | -30.12% | -61.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +125.35% | — |
| Average volume | 622.92K | 726.75K |
| Shares outstanding | 63.70M | 71.85M |
| Employees | 293 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed SIGA by 159.8 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
MGNX vs SIGA FAQ
Which is bigger, MacroGenics or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $235.67M compared with $226.14M for MacroGenics (MGNX).
Which stock has performed better over the past year, MGNX or SIGA?
MGNX returned +99.44% over the past 12 months, compared with -60.39% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.